Rodrigues Filipe B, Duarte Gonçalo S, Costa João, Ferreira Joaquim J, Wild Edward J
Huntington's Disease Centre, Institute of Neurology, University College London, Russell Square 10-12, London, WC1B 5EH UK.
Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
J Clin Mov Disord. 2017 Nov 22;4:19. doi: 10.1186/s40734-017-0067-x. eCollection 2017.
Here we discuss the report by Claassen and colleagues describing an indirect treatment comparison between tetrabenazine and deutetrabenazine for chorea in Huntington's disease using individual patient data. We note the potential for discrepancies in apparently statistically significant findings, due to the rank reversal phenomenon. We provide some cautionary observations and suggestions concerning the limitations of indirect comparisons and the low likelihood that good quality evidence will become available to guide clinical decision comparing these two agents.
在此，我们讨论了Claassen及其同事的报告，该报告使用个体患者数据描述了丁苯那嗪和氘代丁苯那嗪治疗亨廷顿舞蹈症中舞蹈症的间接治疗比较。我们注意到，由于秩反转现象，在表面上具有统计学显著意义的结果中可能存在差异。我们针对间接比较的局限性以及获得高质量证据以指导比较这两种药物的临床决策的可能性较低的情况，给出了一些警示性的观察结果和建议。
